structure of tirzepatide molecular formula of tirzepatide is C225H348N48O68 - Mounjaro TZP is a 39-peptide The Intricate Structure of Tirzepatide: A Dual GIP/GLP-1 Receptor Agonist

Tirzepatide中文 Tirzepatide, a groundbreaking therapeutic agent, has garnered significant attention in the medical community for its innovative approach to managing type 2 diabetes and obesity. At its core, the efficacy of Tirzepatide lies in its unique and precisely engineered structure. This article delves into the detailed structure of Tirzepatide, exploring its molecular composition, key features, and the scientific underpinnings that enable its dual receptor agonism. Understanding this molecular structure of Tirzepatide is crucial for appreciating its therapeutic potential and its distinct position among incretin-based therapies2025年3月7日—At the molecular level, Tirzepatide is a39–amino acid peptideengineered to mimic both GIP and GLP-1 while incorporating structural ....

The molecular formula of Tirzepatide is C225H348N48O68, with a corresponding molecular weight of approximately 4813.45 Daltons. This complex composition points to a sophisticated peptide-based molecule. At its foundation, Tirzepatide is a linear peptide consisting of 39 amino acids, often abbreviated as TZP is a 39-peptide. This peptide chain is not a simple replication of naturally occurring hormones but rather a meticulously designed compositeOverview of Tirzepatide and Semaglutide. It incorporates elements that enhance stability, receptor binding, and pharmacological activity, drawing inspiration from native incretins.217806Orig1s000 - accessdata.fda.gov

A significant aspect of Tirzepatide's structure involves modifications to the standard amino acid sequence. Notably, it features two non-coded amino acid residues at positions 2 and 13Tirzepatide · Product NameTirzepatide · CAS2023788-19-2 ·MFC225H348N48O68· MW4813 · EINECS200-001-8 · MOL File2023788-19-2.mol .... These are \u03b1-aminoisobutyric acid (Aib) residues, which depart from the 20 common proteinogenic amino acids. The inclusion of Aib is a deliberate strategy to increase resistance to enzymatic degradation, thereby prolonging the molecule's half-life and enhancing its pharmacokinetic profile. This strategic substitution contributes to Tirzepatide's sustained action within the bodyIllustration showing themolecular structure of tirzepatide, a drug used to treat type 2 diabetes and obesity..

Further contributing to its extended duration of action is a C20 fatty diacid component attached to the side chain nitrogen of Lys20Tzp. This modification, often described as being linked via a linker of L-\u03b1-glutamic acid in scientific literature, allows Tirzepatide to bind to albumin in the bloodstream. This albumin binding acts as a reservoir, slowing down the clearance of the peptide and further extending its therapeutic window. The presence of this lipophilic appendage is a critical structural determinant for Tirzepatide's prolonged half-life, distinguishing it from shorter-acting peptides.

The tertiary structure of Tirzepatide is described as being consistent with a natively folded peptide, and its secondary structure is predominantly \u03b1-helical. This helical propensity is important for its interaction with its target receptors.2025年8月22日—Tirzepatide is alinear peptide containing 39 amino acids, optimized based on the natural GIP structure, similar in size to GIP and GLP-1. The ... Investigating the Cryo-EM structure of the tirzepatide bound to its cognate receptors has provided invaluable insights. Studies have determined cryo-EM structures of tirzepatide-bound GIPR and GLP-1R, visualizing the precise molecular interactions that underpin its dual agonist activity.Within this context, we report here the crystal structure of the (R)-(2-tert-butoxycarbonyl)amino-1-oxo-3-phenyl)propyl)-1-cyclopentene(1), synthesis of which ... These structural analyses reveal how Tirzepatide engages with both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor.

Tirzepatide's design is rooted in its function as a dual agonist for both the insulinotropic polypeptide (GIP) and GLP-1 receptors. This dual action is key to its significant therapeutic effects. By simultaneously activating these two incretin pathways, Tirzepatide mimics the complex hormonal regulation involved in glucose homeostasis and appetite control. This combined stimulation leads to enhanced insulin secretion, reduced glucagon levels, delayed gastric emptying, and increased satiety – all contributing to improved glycemic control and weight management.

The structure of Tirzepatide also includes various other specific substitutions and modifications that optimize its binding affinity and efficacy at both the GIP and GLP-1 receptors. While the exact sequence is proprietary, research indicates it contains fragments inspired by both native incretins and related peptides like Extendin-42023年10月13日—The secondary structure of tirzepatide ispredominantly α-helical, the tertiary structure is consistent with a natively folded peptide, and .... The exact chemical nomenclature, such as C225H348N48O68 or MFC225H348N48O68, precisely defines its atomic compositionTirzepatide: A Systematic Update.

In summary, the structure of Tirzepatide is a testament to modern peptide engineering.Tirzepatide CAS#: 2023788-19-2 This 39-amino acid peptide combines native-like sequences with non-canonical amino acids and a C20 fatty diacid modification. This intricate design, characterized by its linear peptide containing 39 amino acids backbone, specific amino acid substitutions, and lipidation, endows Tirzepatide with its potent dual agonism and extended duration of action. The detailed visualization of its molecular structure through techniques like cryo-electron microscopy continues to deepen our understanding of how this remarkable molecule exerts its therapeutic effects, marking a significant advancement in the treatment of metabolic conditions. The development and understanding of Tirzepatide underscore the power of enanti in drug discovery and its potential to address complex health challengesDatabase: EMDB / ID: EMD-31603. Structure visualization. Downloads & links ·Cryo-EM structure of the tirzepatide(LY3298176)-bound human GLP-1R-Gs complex..